Navitoclax was re-engineered to create a more selective BCL-2 inhibitor, venetoclax (ABT-199), which also acts as a BH3 mimetic but shows higher specificity for BCL2 and lower specificity for BCL-XL, decreasing the rate of thrombocytopenia [107]. The gene discussed is BCL2; the disease is Thrombocytopenia.